Syed Abutalib

2 months ago | ascopost.com | Syed Abutalib |Alex Herrera |Álex Herrera

“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.”—Muhammad AliLong-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of adjuvant mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)-like chemotherapies improved progression-free survival rates.

Apr 25, 2024 | ascopost.com | Syed Abutalib |Alex Herrera |Álex Herrera

Alex Francisco Herrera, MDClassical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and long-term treatment-related morbidity, enhancing quality of life, and improving poor outcomes in patients older than age 60.

Aug 28, 2023 | ascopost.com | Syed Abutalib |Amer M Zeidan

“Perfection is attained by slow degrees; it requires the hand of time.” —Voltaire Amer M. Zeidan, MBBS, MHSDr. Abutalib is Director of the Malignant Hematology and Transplantation & Cellular Therapy Programs at the Advocate/Aurora St. Luke’s Medical Center, Milwaukee, and Associate Professor at Rosalind Franklin University of Medicine and Science, Chicago.